|
A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. |
| |
Katherine M. Bell-McGuinn |
Consulting or Advisory Role - Clovis Oncology |
Travel, Accommodations, Expenses - Abbvie |
| |
|
Consulting or Advisory Role - Ultragenyx Pharmaceuticals |
| |
|
Honoraria - Merck Serono; Millennium |
Consulting or Advisory Role - Merck Serono; Millennium |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Advaxis; Amgen (Inst); AstraZeneca; Genentech/Roche; Immunogen |
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
Consulting or Advisory Role - CritiTech; Insys Therapeutics |
Research Funding - Abbott Biotherapeutics |
| |
|
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Millennium (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Abbvie |
| |
|
|
Stock and Other Ownership Interests - Abbvie |
| |
|
Consulting or Advisory Role - AstraZeneca |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca |